<a href="https://www.tcspharms.com/pro/Dalbavancin_171500-79-1_api_powder_price_dose.html" rel="nofollow ugc">dalbavancin</a> (inn, trade names dalvance in the us and xydalba in the eu) is a novel second-generation lipoglycopeptide antibiotic medication. it belongs to the same class as vancomycin, the most widely used and one of the few treatments available to patients infected with methicillin-resistant staphylococcus aureus (mrsa). 
 
dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin..it is derived from a complex of glycopeptide antibiotics, referred to as a-40926, that is produced by a new strain of actinomadura. dalbavancin has been referred to in the scientific literature by a series of names: mdl-63397, a-!-1, bi-397, ver-001. these different labels reflected where the research had been carried out: mdl representing merrell-dow-lepetit, where the initial complex was discovered; bi referring to biosearch italia where dalbavancin itself was first synthesized; ver referring to versicor (which biosearch italia merged with to create vicuron pharmaceuticals). the phase 1, 2 and 3 clinical trials were carried out of by vicuron and the initial nda filed. vicuron was acquired by pfizer in 2005, which decided to not further develop dalbavancin at that time, subsequently selling the rights to durata therapeutics in 2009. 
 
it possesses in vitro activity against a variety of gram-positive pathogens including mrsa and methicillin-resistant staphylococcus epidermidis (mrse). it is a once-weekly, two-dose antibiotic, the rights to which actavis acquired when it bought durata therapeutics in 2014. 
 
the u.s. food and drug administration (fda) approved dalbavancin in may 2014, for the treatment of acute bacterial skin and skin structure infections (absssis) caused by certain susceptible bacteria such as staphylococcus aureus including methicillin-susceptible and methicillin-resistant strains of streptococcus pyogenes, in intravenous dosage form.